Navigation Links
Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies
Date:9/24/2013

EXTON, Pa., Sept. 24, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. neurologists report significantly greater overall physician satisfaction with Biogen Idec's recently-launched oral disease-modifying therapy (DMT) Tecfidera than with most other DMTs approved for the treatment of relapsing forms of multiple sclerosis (MS). These other agents include platform injectables such as interferon-beta therapies and Teva's Copaxone, as well as other oral DMTs—Aubagio from Genzyme (a Sanofi company) and Novartis's Gilenya. This finding likely reflects respondents' high rating of Tecfidera on several key performance attributes in the areas of efficacy and patient benefits compared with other approved agents. Nevertheless, Copaxone—the current patient share leader among respondents' DMT-treated MS patients—still ranks as respondents' most preferred brand for the treatment of relapsing-remitting multiple sclerosis (RR-MS), a perception driven by the drug's long-term safety and tolerability/side effect profile.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The recently published TreatmentTrends: Multiple Sclerosis Q3 2013 (US) report also finds that, if only two late-stage emerging products were to launch for the treatment of MS (out of six products assessed), more than 45 percent of surveyed neurologists select Teva's Copaxone 40 mg three-times-weekly (3TW) and Genzyme/Bayer HealthCare's Lemtrada as bringing the most value to treatment; slightly fewer also chose Teva/Active Biotech's laquinimod. Data show that neurologists' self-reported familiarity with the product and its predecessor drives the perceived value of Copaxone 40 mg 3TW, while efficacy and administration, respectively, are the most frequently-cited reasons for respondents' perceived value of Lemtrada and laquinimod.  

The findings also reveal that surveyed neurologists expect total patient share for oral DMTs—Aubagio, Gilenya, and Tecfidera—to increase significantly among DMT-treated RR-MS patients over the next six months, mainly at the expense of the interferon-beta brands and Copaxone. During this time, neurologists expect the overall patient share for oral DMTs to more than double from 14 percent to 30 percent overall, with most of this growth coming from anticipated use of Tecfidera. Use of Biogen Idec's Tysabri, which ranks highest on multiple efficacy and other key performance attributes, is also expected to increase significantly.

"With the advent of oral DMTs and new DMT alternatives on the horizon for the treatment of MS, surveyed neurologists indicate further change in clinical practice is coming," said Senior Director of CNS Disorders Jonathan W. Searles. "As part of this change, our findings signal neurologists' continued reliance on products demonstrating strong safety, but also a growing acceptance of agents that offer robust efficacy at potentially greater risk, if such risks are defined, manageable, and clinically justified."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
2. A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
3. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
4. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
5. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
6. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
7. Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
8. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
9. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
10. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
11. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):